Lantheus (NASDAQ:LNTH) Sets New 52-Week High – Still a Buy?

Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) reached a new 52-week high during trading on Tuesday . The stock traded as high as $111.52 and last traded at $111.2550, with a volume of 83991 shares traded. The stock had previously closed at $109.58.

Wall Street Analyst Weigh In

Several brokerages have weighed in on LNTH. William Blair reiterated an “outperform” rating on shares of Lantheus in a report on Tuesday, March 17th. Citizens Jmp restated a “market outperform” rating and set a $115.00 price objective on shares of Lantheus in a report on Monday. Citigroup reaffirmed an “outperform” rating on shares of Lantheus in a research report on Friday, May 8th. B. Riley Financial reiterated a “buy” rating on shares of Lantheus in a research note on Friday, May 1st. Finally, Jefferies Financial Group reiterated a “buy” rating and set a $110.00 target price on shares of Lantheus in a research report on Tuesday, March 17th. Eight equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $101.86.

Lantheus Stock Up 0.6%

The firm has a market capitalization of $7.14 billion, a PE ratio of 26.50 and a beta of -0.03. The company has a current ratio of 2.83, a quick ratio of 2.64 and a debt-to-equity ratio of 0.47. The firm has a 50-day moving average of $97.43 and a two-hundred day moving average of $81.01.

Lantheus (NASDAQ:LNTH) last posted its quarterly earnings results on Thursday, May 7th. The medical equipment provider reported $1.46 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.25 by $0.21. The firm had revenue of $377.33 million during the quarter, compared to the consensus estimate of $354.48 million. Lantheus had a return on equity of 29.32% and a net margin of 18.05%.The firm’s quarterly revenue was up 1.2% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.53 earnings per share. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. On average, equities research analysts forecast that Lantheus Holdings, Inc. will post 4.49 EPS for the current year.

Institutional Trading of Lantheus

A number of institutional investors and hedge funds have recently bought and sold shares of the business. M&T Bank Corp acquired a new position in Lantheus during the fourth quarter valued at approximately $370,950,000. Farallon Capital Management LLC increased its position in shares of Lantheus by 56.1% in the fourth quarter. Farallon Capital Management LLC now owns 5,427,479 shares of the medical equipment provider’s stock worth $361,199,000 after acquiring an additional 1,950,252 shares in the last quarter. Norges Bank purchased a new position in shares of Lantheus in the 4th quarter valued at $76,197,000. Freestone Grove Partners LP raised its stake in shares of Lantheus by 4,114.8% in the 4th quarter. Freestone Grove Partners LP now owns 608,526 shares of the medical equipment provider’s stock valued at $40,497,000 after acquiring an additional 594,088 shares during the period. Finally, Healthcare of Ontario Pension Plan Trust Fund lifted its holdings in shares of Lantheus by 686.1% during the 1st quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 598,857 shares of the medical equipment provider’s stock valued at $45,423,000 after acquiring an additional 522,678 shares in the last quarter. Institutional investors and hedge funds own 99.06% of the company’s stock.

Lantheus Company Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.